Why energy fails
Sustained energy is the output of three systems that have to be working in concert: mitochondrial ATP production (the actual energy supply), HPA-axis cortisol rhythm (the system that allocates energy across the day), and central nervous system activation (the system that translates available energy into perceived alertness). When fatigue persists despite adequate sleep, the failure is almost always in one of those three layers — not in the will to push through it.
Mitochondrial dysfunction is the most under-diagnosed cause of adult fatigue. Mitochondria produce ATP through oxidative phosphorylation, and when their machinery is compromised by oxidative damage, NAD+ depletion, or insulin resistance, every cell in the body runs on a reduced energy budget. The clinical signature is a fatigue that doesn't respond to rest — you can sleep ten hours and still feel exhausted because the cellular energy supply is the bottleneck, not sleep debt.
HPA-axis dysregulation is the second most common pattern. Chronic stress flattens the diurnal cortisol curve: morning cortisol is low (the "I can't get out of bed" feeling), evening cortisol is paradoxically elevated (the "wired-but-tired" pattern), and the system loses its day-night signal entirely. This is the fatigue most commonly diagnosed as "burnout."
The third layer is CNS activation — specifically, the BDNF, dopamine, and noradrenergic pathways that drive subjective alertness. Cognitive fatigue without physical fatigue often traces here.
Each layer has a peptide approach with published mechanistic evidence behind it. The peptide that's right for you depends on which layer is the bottleneck.
MOTS-c: the mitochondrial peptide
MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA gene of the mitochondrial genome. It was identified by the Cohen lab at USC in 2015 (Lee et al., Cell Metabolism, PMID: 25738459) and has since accumulated a strong preclinical literature on its role as a metabolic master regulator.
Mechanistically, MOTS-c activates AMP-activated protein kinase (AMPK), the cellular energy sensor that triggers a switch from glucose-storage mode (anabolic) to glucose-burning mode (catabolic). It improves insulin sensitivity, promotes mitochondrial biogenesis, and protects against age-related metabolic decline. The mouse evidence for restored exercise capacity in aged animals is striking; the human data is earlier-stage but increasingly supportive (Reynolds et al., Nature Communications, 2021, PMID: 33531470).
For someone whose fatigue presents as exercise intolerance and post-exertional malaise — the metabolic-syndrome adjacent profile — MOTS-c is the first-line consideration. Typical research protocol: 5–10 mg subcutaneously, two to three times per week, in 8–12 week cycles. See dosing and timing notes on the MOTS-c profile.
NAD+: precursor or peptide?
NAD+ (nicotinamide adenine dinucleotide) is technically a coenzyme rather than a peptide, but it's treated as a peptide-adjacent therapy because of its standard injectable administration and the overlap with the peptide therapeutic community. NAD+ declines roughly 50% between ages 30 and 60, driven by increased consumption (CD38, SIRT activity, DNA repair) and decreased synthesis. The clinical signature of low NAD+ overlaps heavily with mitochondrial dysfunction: persistent fatigue, exercise intolerance, slowed cognition, and a reduced metabolic flexibility (Yoshino et al., Cell Metabolism, 2018, PMID: 29551589).
Replenishment via IV or SC NAD+ has accumulating clinical evidence for energy restoration in chronically fatigued adults, particularly those with documented mitochondrial dysfunction or post-viral fatigue syndromes. Oral precursors (NR, NMN) also work but raise serum NAD+ less reliably than direct IV/SC infusion.
Semax: cognitive activation
Semax is a heptapeptide developed by the Russian Institute of Molecular Genetics, derived from ACTH(4–10). It modulates BDNF, dopamine, and noradrenaline signaling in the brain, and has been used clinically in Russia for over three decades for stroke recovery and cognitive enhancement (Medvedev et al., 2009).
For fatigue with a heavy cognitive-fatigue component — brain fog, slow processing, post-concussion or post-viral cognitive lag — Semax has the cleanest published evidence of any peptide. Typical protocol: 250–600 mcg intranasal in the morning, optionally with a second dose mid-afternoon. See the Semax profile for details.
Tesamorelin and the GH-axis
For older adults whose fatigue includes the classic GH-deficient features (visceral adiposity, poor sleep, sarcopenia), Tesamorelin and the GH-pair (CJC-1295 + Ipamorelin) restore the nighttime GH pulse and indirectly the energy budget. This is a slower-acting layer than MOTS-c or Semax — improvements typically appear in weeks 4–8 — but the durability is good.
Stacks
The combinations with the strongest mechanistic rationale:
- MOTS-c + NAD+ — mitochondrial double-up. Use when bioenergetics is the suspected bottleneck.
- Semax + MOTS-c — cognitive activation plus metabolic. The most common pairing for post-viral and burnout-spectrum fatigue.
- CJC-1295/Ipamorelin + MOTS-c — for older adults with mixed GH and metabolic profile.
For the full logic of stacking, see the stacking guide.
Protocols
Beginner (single-peptide trial, 4 weeks). Pick one — MOTS-c if metabolic, Semax if cognitive. Run for three weeks, washout for one, re-evaluate. Track energy on a 1–10 scale daily; energy is harder to subjectively assess than sleep, so quantification matters.
Intermediate (mitochondrial stack, 12 weeks). MOTS-c 10 mg SC twice weekly. NAD+ 100 mg SC weekly. Resistance training 2x/week minimum.
Advanced (full HPA-mitochondrial-cognitive stack, 12–16 weeks). MOTS-c + NAD+ + Semax + the GH-pair for older adults. Quarterly labs: fasting insulin, A1c, IGF-1, cortisol AM, comprehensive metabolic.
Safety
MOTS-c, NAD+, and Semax all have favorable safety profiles in published research. NAD+ infusion can cause transient flushing and chest tightness during administration; this resolves with slower infusion. MOTS-c may cause initial-week flushing as mitochondrial activity ramps. Semax has no notable side effects below 1500 mcg/day. Always consult a clinician for protocols over 8 weeks.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015. PMID: 25738459.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PMID: 33531470.
- Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018. PMID: 29551589.
- Medvedev VE, Volel BA. Effectiveness of melatonergic antidepressants and Semax in cognitive disorders. 2009.